Head-To-Head Review: INVO Fertility (NASDAQ:IVF) versus Cigna Group (NYSE:CI)

Cigna Group (NYSE:CI) and INVO Fertility (NASDAQ:IVF) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Profitability

This table compares Cigna Group and INVO Fertility’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cigna Group	2.27%	19.75%	5.34%
INVO Fertility	-116.29%	-85.54%	-31.05%

Volatility & Risk

Cigna Group has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500.

Earnings and Valuation

This table compares Cigna Group and INVO Fertility”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cigna Group	$274.90 billion	0.29	$5.96 billion	$24.17	12.33
INVO Fertility	$6.84 million	0.18	-$25.13 million	($33.83)	-0.06

Cigna Group has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than Cigna Group, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

87.0% of Cigna Group shares are held by institutional investors. Comparatively, 12.0% of INVO Fertility shares are held by institutional investors. 0.6% of Cigna Group shares are held by company insiders. Comparatively, 0.4% of INVO Fertility shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cigna Group and INVO Fertility, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cigna Group	0	8	15	0	2.65
INVO Fertility	1	0	0	1	2.50

Cigna Group currently has a consensus target price of $338.24, suggesting a potential upside of 13.45%. INVO Fertility has a consensus target price of $320.00, suggesting a potential upside of 16,653.93%. Given INVO Fertility’s higher probable upside, analysts plainly believe INVO Fertility is more favorable than Cigna Group.

Summary

Cigna Group beats INVO Fertility on 12 of the 15 factors compared between the two stocks.

About Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.